Biogen’s Pipeline: Alzheimer’s Is In, Stroke Is Out
Executive Summary
The company is prioritizing investment in the launches of Leqembi, zuranolone and newly approved Qalsody as well as key pipeline assets, while discontinuing investment in two stroke programs.
You may also be interested in...
Sun Backs India-First Stroke Drug From Pharmazz
Sun debuts Pharmazz Inc’s new stroke drug sovateltide in India at under $20/ vial. The selective endothelin-B receptor agonist, which can be administered up to 24 hours post cerebral ischemic stroke, is also being studied in Alzheimer’s disease.
Biogen’s Latest Leadership Change Hints At Immunology Ambitions
New head of research Jane Grogan comes to Biogen from start-ups Graphite Bio and ArsenalBio, and previously held leadership positions in autoimmune and oncology R&D at Genentech.
Biogen Braces For Cost Cuts As Business Transition Continues
The company announced a new $1bn cost savings program that will result in 1,000 job cuts; $300m of the savings will be reinvested in new drug launches and R&D.